Minimal Residual Disease (MRD) testing is crucial for tracking leukemia and lymphoma, helping detect cancer recurrence with high precision. Many U.S. laboratories and medical institutions offer MRD testing services, making it an essential component of oncology diagnostics and treatment monitoring. Advanced technologies like Next-Generation Sequencing (NGS), digital PCR, and flow cytometry have enhanced MRD detection, improving sensitivity and early intervention. As MRD testing continues to evolve, its role in precision medicine and cancer management is expanding, driving widespread adoption in clinical settings.
According to BIS research U.S. Minimal Residual Disease (MRD) testing market is projected to reach $1,667.5 million by 2030, growing at a CAGR of 14.18% (2024-2030). In 2023, U.S. testing facilities held a 39.53% share of the global MRD testing market, reflecting strong demand for high-precision cancer monitoring. Numerous U.S. laboratories provide MRD testing, with factors such as technology used, test accuracy, and clinical expertise influencing patient choices. The rising adoption of Next-Generation Sequencing (NGS), digital PCR, and flow cytometry continues to drive market growth, making MRD testing a key component of precision oncology.
The growing adoption of advanced technologies is transforming MRD testing, enhancing accuracy, accessibility, and personalized cancer treatment. By leveraging in-depth genetic data, MRD testing is shaping precision medicine in oncology.
The U.S. MRD testing market is driven by innovation, strategic collaborations, and personalized medicine advancements. While cost barriers and sensitivity challenges remain, progress in companion diagnostics, Medicare coverage, and clinical trials is expanding accessibility. By overcoming these hurdles, MRD testing is poised to revolutionize cancer care and patient outcomes in the coming years.
